Bliss GVS Pharma Board of Directors
Get the latest insights into the leadership at Bliss GVS Pharma. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Nandkumar K Chodankar | Chairman & Ind.Director |
| Mr. Gagan Harsh Sharma | Managing Director |
| Dr. Vibha Gagan Sharma | Whole Time Director |
| Mrs. Shruti Vishal Rao | Whole Time Director |
| Mr. Santosh L Parab | Independent Director |
| Ms. Shilpa Bhatia | Independent Woman Director |
Bliss GVS Pharma Share price
BLISSGVS
156.21
2.45 (-1.54%)NSE
BSE
Last updated on 4 Sep, 2025 | 15:59 IST
BUYSELL
Today's High
161.25
Today's Low
155.74
52 Week Low
106.04
52 Week High
190.97
The current prices are delayed, login to your account for live prices
LoginBliss GVS Pharma FAQs
The board at Bliss GVS Pharma consists of experienced professionals, including Mr. Nandkumar K Chodankar , Mr. Gagan Harsh Sharma , and others, overseeing the company’s strategic and corporate governance.
Directors at Bliss GVS Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Nandkumar K Chodankar is the current chairman at Bliss GVS Pharma.
Executive directors at Bliss GVS Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Bliss GVS Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Bliss GVS Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.